RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Stoke Therapeutics Stock

Stoke Therapeutics Employees 2024

Stoke Therapeutics Employees

79

Ticker

STOK

ISIN

US86150R1077

WKN

A2PLTL

In 2024, Stoke Therapeutics employed 79 people, a 0% change from the 79 number of employees in the previous year.

Stoke Therapeutics Aktienanalyse

What does Stoke Therapeutics do?

Stoke Therapeutics Inc is a biopharmaceutical company founded in 2018 by experienced scientists to develop innovative therapeutic approaches for rare genetic diseases. The company's headquarters is located in Bedford, Massachusetts, and since its inception, it has continuously invested to expand its business and its development process. In 2019, the company announced a financing round of $90 million to advance the development of its pipeline and clinical trials. Stoke Therapeutics specializes in the development of therapeutics for the treatment of rare genetic diseases caused by mutations in haploinsufficiency genes. These diseases are caused by mutations in one of the two genes that code for a specific protein. Since a single defective gene is not sufficient to maintain the normal functions of a protein, serious health problems arise. Stoke's therapeutics aim to replace the missing gene product by targeted stimulation of the healthy gene. This is achieved through the development of antisense oligonucleotide-based therapeutics. Antisense oligonucleotides are small DNA-like molecules that are able to address, recognize, and bind to specific genes. By binding to the healthy gene, they can promote its expression and thereby replace the missing protein. The company's pipeline currently includes a range of products at various stages of development, including preclinical and clinical trials. The following products are the most important: STK-001: A product developed for the treatment of severe forms of Dravet syndrome. Dravet syndrome is a rare genetic disease characterized by seizures, developmental delays, and other neurological symptoms. STK-002: A product for the treatment of haploinsufficiency in STING1-associated vasculopathic syndrome (SAVS). SAVS is a rare genetic disease characterized by cardiovascular disorders and increased susceptibility to infections. STK-005: A product for the treatment of haploinsufficiency in adrenoleukodystrophy (ALD). ALD is a rare disease characterized by inflammatory and degenerative changes in the nervous system. Due to its innovative technology and focus on rare genetic diseases, Stoke Therapeutics has attracted the attention of many investors and potential partners. In 2020, the company entered into collaboration agreements with Roche Holdings and Ribometrix Inc to accelerate the development and commercialization of its therapeutics. Overall, Stoke Therapeutics has a promising future as it is able to provide a much-needed treatment option for patients with rare genetic diseases who currently have no effective therapies available. Stoke Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Stoke Therapeutics's Employee Base

Stoke Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Stoke Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Stoke Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Stoke Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Stoke Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Stoke Therapeutics stock

How many employees does Stoke Therapeutics have this year?

Stoke Therapeutics has 79 undefined employees this year.

How many employees did Stoke Therapeutics have compared to the previous year?

Compared to the previous year, Stoke Therapeutics had 0% more employees.

What impact did the number of employees have on the company Stoke Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Stoke Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Stoke Therapeutics?

The number of employees can also have an impact on investors of Stoke Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Stoke Therapeutics affect the company?

An increase in equity of Stoke Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Stoke Therapeutics's equity affect the company?

A reduction in equity of Stoke Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Stoke Therapeutics?

Some factors that can influence the equity of Stoke Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Stoke Therapeutics so important for investors?

The equity of Stoke Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Stoke Therapeutics influence the company?

The number of employees at Stoke Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Stoke Therapeutics evolved in recent years?

In recent years, the number of employees at Stoke Therapeutics has changed by 0.

How many employees does Stoke Therapeutics currently have?

Stoke Therapeutics currently has 79 undefined employees.

Why is the number of employees important for investors of Stoke Therapeutics?

The number of employees is important for investors of Stoke Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Stoke Therapeutics take to change the number of employees?

To change the number of employees, Stoke Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Stoke Therapeutics pay?

Over the past 12 months, Stoke Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stoke Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Stoke Therapeutics?

The current dividend yield of Stoke Therapeutics is .

When does Stoke Therapeutics pay dividends?

Stoke Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Stoke Therapeutics?

Stoke Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Stoke Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Stoke Therapeutics located?

Stoke Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stoke Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stoke Therapeutics from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Stoke Therapeutics pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of Stoke Therapeutics in the year 2023?

In the year 2023, Stoke Therapeutics distributed 0 USD as dividends.

In which currency does Stoke Therapeutics pay out the dividend?

The dividends of Stoke Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Stoke Therapeutics

Our stock analysis for Stoke Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stoke Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.